- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01404988
Veterans Intensive Personalized Treatment in Heart Failure (VIP)
VIP (Veterans Intensive Personalized) Treatment in Heart Failure
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES: In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life (QOL) in veterans with heart failure (HF). This theory-based pilot 3-arm randomized controlled trial (RCT) will base one active arm on the Transtheoretical Model (TTM), while the other active arm will add environmental (built and human) tailoring to TTM. The overarching hypothesis driving this proposal is that a behavioral intervention (BI), which uses the TTM, or a behavioral and environment-tailored intervention (BEI) will lower HF recurrence and improve QOL by better medication and diet adherence compared to attention control.
RESEARCH DESIGN: This is a practice-based RCT to test the effect of BI and BEI on medication and diet adherence. The study is embedded in typical VA healthcare with all 3 arms incorporating the enhancements in HF care that have been implemented including the Patient Aligned Care Teams (PACT), system redesign methods to improve HF care, ongoing HF quality improvement and Telehealth. We will randomize 99 participants equally to BI, BEI and AP. All analyses will be intent to treat.
METHODOLOGY: The study sites will be the VAMC's at Manhattan and Brooklyn. Participants will be veterans with classes I-III HF with prescribed HF medication for 6 months. Men and women ( 21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III are eligible. They must have an available phone and 2 clinic visits in the previous 1.5 years. Patients with poor short-term survival (< 1 year), recent major surgery (< 3 months), temporarily in the area, or those unable to provide consent will be excluded. After being screened for eligibility, participants will come in for 2 study visits over the course of 6 months which will last about 1.5-2 hours. At each visit, a research assistant (RA) will administer a questionnaire assessing health behaviors including diet, exercise and medication and quality of life. The RAs will also measure height, weight, take 6 BP readings, and send patients to the lab for blood and urine samples. After the first clinic visit, participants will be randomized to one of three telephone groups. All participants will receive 1 phone call per month for 6 months which will last approximately 30-40 minutes. 1) The BI group will receive TTM stage-matched counseling. The interventionist will assess how ready patients are for change in terms of diet, medication, and exercise adherence and deliver a tailored intervention discussing adherence barriers. 2) In the BEI, in addition to using the TTM, the intervention will tailor environmental factors, such as availability of healthy food stores, recreational facilities, and support from caregivers in helping participants follow treatment recommendations. We will speak with participant's caregivers to educate them on heart failure as well. The caregivers will receive a call every 2 months (3 in total) lasting approximately 20-30 minutes. 3) The control group will receive monthly telephone calls during which they will receive general health education. Our primary analytic goal is to estimate the medication adherence rate and QOL to power a larger study. We will also perform 1-sample Exact Binomial Tests comparing the active arms to the expected inactive control rate of 47%. Since this is a pilot study, we will use a 5% type 1 error rate (2-sided) for each test. All analyses will be intent to treat.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10010
- VA New York Harbor Health Care System
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men and women (21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III.
- They must have an available phone and 2 clinic visits in the previous 1.5 years.
Exclusion Criteria:
- Patients with poor short-term survival (< 1 year)
- recent major surgery (< 3 months)
- temporarily in the area
- or those unable to provide consent will be excluded.
- Patients excluded and reason for exclusion will be recorded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Telephone-Delivered BI
Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
|
Behavioral Intervention will be delivered over the phone.
|
|
Sperimentale: Telephone-Delivered BEI
Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring.
Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities.
Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support.
Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
|
Behavioral and Environmental Intervention will be delivered over the phone
|
|
Comparatore placebo: Telephone-Delivered API
Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
|
Attention Placebo Intervention will be delivered over the phone
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Medication Adherence (Refill Compliance for All HF Medications)
Lasso di tempo: 6 months from baseline visit
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months from baseline visit
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adherence to ACE Inhibitors and ARB
Lasso di tempo: 6 months after baseline
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months after baseline
|
|
Adherence to Beta Blockers
Lasso di tempo: 6 months from baseline
|
Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take.
At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days.
This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day.
To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed".
If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent.
This absolute value is referred to as a "Gap".
The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
|
6 months from baseline
|
|
Self-reported Medication Adherence
Lasso di tempo: 6 months from baseline
|
Assessed using Morisky medication-taking scale.
Higher score corresponds to worse adherence.
|
6 months from baseline
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Sundar Natarajan, MD MSc, VA New York Harbor Health Care System
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RRP 11-238
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Arresto cardiaco
-
Region SkaneIscrizione su invitoInsufficienza cardiaca Classe II della New York Heart Association (NYHA). | Insufficienza cardiaca Classe III della New York Heart Association (NYHA).Svezia
-
Yonsei UniversityReclutamentoIschemic Heart Disease | Cardiopatia Non IschemicaCorea del Sud
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... e altri collaboratoriTerminatoInsufficienza cardiaca, sistolica | Insufficienza cardiaca con frazione di eiezione ridotta | Scompenso cardiaco Classe IV della New York Heart Association | Scompenso cardiaco Classe III della New York Heart AssociationPolonia
-
University of WashingtonAmerican Heart AssociationCompletatoInsufficienza cardiaca, congestizia | Alterazione mitocondriale | Scompenso cardiaco Classe IV della New York Heart AssociationStati Uniti
-
Portuguese Association of Interventional CardiologyMedtronicReclutamentoStenosi Aortica Sintomatica Grave (Definita come Classe New York Heart Association (NYHA) ≥ II)Portogallo
Prove cliniche su Telephone-Delivered BI
-
National University of Ireland, Galway, IrelandUniversity College Hospital Galway; Brothers of Charity Services Galway IrelandNon ancora reclutamentoDisabilità intellettive (F70-F79) | Educazione alla prevenzione e alla consapevolezza del cancro | Consapevolezza del cancro al senoIrlanda
-
University of LiverpoolLondon School of Hygiene and Tropical Medicine; National Institute of Mental...Completato
-
Boehringer IngelheimCompletato
-
Washington University School of MedicineNational Institute on Drug Abuse (NIDA)CompletatoMalattie trasmesse sessualmente | HIV | Abuso di sostanze
-
Boehringer IngelheimCompletato
-
Boehringer IngelheimCompletato
-
Boehringer IngelheimAttivo, non reclutanteMelanoma | Carcinoma polmonare non a piccole cellule (NSCLC) | Carcinoma a cellule squamose della testa e del collo (HNSCC)Olanda
-
Boehringer IngelheimCompletato
-
Boehringer IngelheimCompletato
-
Boehringer IngelheimCompletato